DoseMe, a portfolio company of private equity firm Fairlong Capital, announced on November 3 its acquisition of Vancouver, Canada-based Firstline.
Firstline is a mobile-first clinical decision support platform. It enables clinicians to rapidly access local, evidence-based infectious disease treatment guidance, susceptibility patterns and antimicrobial stewardship resources.
Headquartered in Jupiter, Florida, DoseMe is a global leader in model-informed precision dosing software. DoseMe optimizes non-time-critical dosing for antimicrobials, oncology agents, immunosuppressants and more, reducing drug-related risks.
The combination of DoseMe and Firstline creates a single, connected experience from therapy selection through personalized dosing, giving clinicians a faster path to optimal care. Financial terms of the deal were not disclosed.
“Firstline is the perfect complement to DoseMe with proven value that provides impact on patient outcomes, hospital ecology, and combating antimicrobial resistance,” said Paul Edwards, CEO of DoseMe. “Together, we support AMS initiatives and speed up optimized patient care decisions by helping clinicians access local stewardship protocols and translate them directly into personalized precision dosing.”
According to data captured in the LevinPro HC database, this transaction marks the 262nd eHealth acquisition of 2025, and the second in the point-of-care support specialty. There were two point-of-care support deals announced throughout 2024. This also marks DoseMe’s first acquisition since it was acquired by Fairlong Capital in February 2023.
